首页> 外文期刊>Ophthalmology >Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study.
【24h】

Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study.

机译:伴有和不伴有局灶性光凝的球周曲安奈德丙酮治疗轻度糖尿病性黄斑水肿的随机试验:一项前瞻性研究。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To provide pilot data on the safety and efficacy of anterior and posterior sub-Tenon injections of triamcinolone either alone or in combination with focal photocoagulation in the treatment of mild diabetic macular edema (DME). DESIGN: Prospective, phase II, multicenter, randomized clinical trial. PARTICIPANTS: One hundred nine patients (129 eyes) with mild DME and visual acuity 20/40 or better. METHODS: The participants were assigned randomly to receive either focal photocoagulation (n = 38), a 20-mg anterior sub-Tenon injection of triamcinolone (n = 23), a 20-mg anterior sub-Tenon injection followed by focal photocoagulation after 4 weeks (n = 25), a 40-mg posterior sub-Tenon injection of triamcinolone (n = 21), or a 40-mg posterior sub-Tenon injection followed by focal photocoagulation after 4 weeks (n = 22). Follow-up visits were performed at 4, 8, 17, and 34 weeks. MAIN OUTCOME MEASURES: Change in visual acuity and retinal thickness measured with optical coherence tomography (OCT). RESULTS: At baseline, mean visual acuity in the study eyes was 20/25 and mean OCT central subfield thickness was 328 mum. Changes in retinal thickening and in visual acuity were not significantly different among the 5 groups at 34 weeks (P = 0.46 and P = 0.94, respectively). There was a suggestion of a greater proportion of eyes having a central subfield thickness less than 250 mum at 17 weeks when the peribulbar triamcinolone was combined with focal photocoagulation. Elevated intraocular pressure and ptosis were adverse effects attributable to the injections. CONCLUSIONS: In cases of DME with good visual acuity, peribulbar triamcinolone, with or without focal photocoagulation, is unlikely to be of substantial benefit. Based on these results, a phase III trial to evaluate the benefit of these treatments for mild DME is not warranted.
机译:目的:提供关于曲安奈德单独或联合局灶光凝治疗轻度糖尿病性黄斑水肿(DME)的前,后Tenon注射的安全性和有效性的初步数据。设计:前瞻性,II期,多中心,随机临床试验。参与者:109例(129眼)轻度DME且视敏度为20/40或更高。方法:随机分配参与者接受局灶性光凝治疗(n = 38),曲安奈德前20 mg前Tenon皮下注射(n = 23),局限性光凝治疗(20 mg前Tenon皮下注射)周(n = 25),曲安奈德后半球Tenon注射40 mg(n = 21)或球后后Tenon注射40 mg(4 = 22)。在第4、8、17和34周进行随访。主要观察指标:用光学相干断层扫描(OCT)测量的视力和视网膜厚度的变化。结果:在基线时,研究眼睛的平均视力为20/25,OCT中心子区域的平均厚度为328微米。 5组在34周时视网膜增厚和视敏度变化无显着差异(分别为P = 0.46和P = 0.94)。有迹象表明,当将周球眼曲安奈德与局部光凝结合时,在17周时有更大比例的眼睛的中央子区域厚度小于250微米。眼内压升高和下垂是注射引起的不良反应。结论:对于具有良好视敏度的DME,伴或不伴有局灶性光凝的球周曲安奈德不太可能具有实质性益处。根据这些结果,没有必要进行III期临床试验来评估这些疗法对轻度DME的益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号